Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Roxee Meds Catalog

Fluoxetine

Medication catalog facts with explicit FDA-approval, off-label, source-limited, and safety context.

Both Catalog complete FDA data linked Rx required Tablet (Chewable) Pegasus Laboratories, Inc. Official label facts Owner quick guide first
Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Storefront facts
Catalog refreshed
May 5, 2026, 10:00 a.m.

These are the storefront facts Roxee uses on browse cards and quick facts.

FDA applications
FDA application data refreshed
May 5, 2026, 10:00 a.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports
Safety data refreshed
May 5, 2026, 10:01 a.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details
Source timing details
  • Storefront facts: Source Roxee | Refreshed May 5, 2026, 10:00 AM UTC
    The storefront fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC

Evidence

Reviewed / Updated / Sources

Reviewed by: Not available

Last reviewed: February 12, 2026

Updated: February 12, 2026, 10:44 PM UTC

Sources:
Image coming soon
Fluoxetine

Fluoxetine

Drug type: Generic ingredient • Branded profile • FDA branded products available

Both Tablet (Chewable) Rx required 100% storefront ready

Species: Both

Manufacturer: Pegasus Laboratories, Inc.

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Fluoxetine

For the treatment of canine separation anxiety in conjunction with a behavior modification plan. Species commonly shown: Both, Dog, No Use Class Stated Or Implied.

Generic name
Fluoxetine
Brand names
Reconcile®, RECONCILE
Manufacturer
Pegasus Laboratories, Inc.
Species
Both, Dog, No Use Class Stated Or Implied
Dosage forms
Tablet (Chewable)
Prescription
Prescription required
Completeness
100%
Validation
Complete
Brand names
Reconcile® RECONCILE
Dosage forms
Tablet (Chewable)

Indications / Uses

For the treatment of canine separation anxiety in conjunction with a behavior modification plan.

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Side Effects

Top reported reactions (openFDA): Vomiting, Lack of efficacy - NOS, Diarrhoea, Seizure NOS, Lethargy (see also Central nervous system depression in Neurological), Decreased appetite.

FAQ

Both, Dog, No Use Class Stated Or Implied

Yes. Roxee shows this as prescription-only.

Tablet (Chewable)

Related Conditions

Separation anxiety

Source Transparency

Add to My Pet's Meds

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For the treatment of canine separation anxiety in conjunction with a behavior modification plan.

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

  • Elevated gamma-glutamyl transferase (1 reports)
  • Elevated alanine aminotransferase (1 reports)
  • Dehydration (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to tell or ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?
Major cautions & emergency warning signs

Side effects to monitor:

  • Elevated gamma-glutamyl transferase
  • Elevated alanine aminotransferase
  • Dehydration

Most reported reactions:

  • Elevated gamma-glutamyl transferase (1 reports)
  • Elevated alanine aminotransferase (1 reports)
  • Dehydration (1 reports)

Emergency warning signs:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Pegasus Laboratories, Inc.
Form: Tablet (Chewable)
Identifiers:
NADA: 141272 NDC Package: 49427-340-44 NDC Package: 49427-340-57 NDC Package: 49427-341-44 NDC Package: 49427-341-57 NDC Package: 49427-342-44 NDC Package: 49427-342-57 NDC Package: 49427-343-44 NDC Package: 49427-343-57 NDC Product: 49427
Source metadata:

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • High: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
18
Species represented
2
Grouped by Body System
Digestive (3) · Diarrhea, Decreased appetite, Appetite loss Neurologic (1) · Unsteady walking (ataxia) Behavior (3) · Circling - behavioural disorder, Behavioral disorder (unspecified), Anxiety Other (25) · Elevated mean corpuscular volume, Elevated gamma-glutamyl transferase, Elevated creatine-kinase
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Other 1 Dog 1
Other 1 Cat 1
Other 1 Dog 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Cat 1
Digestive 1 Dog 1
Other 1 Dog 1

Species coverage: Dog (20) Cat (12)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Neurologic Cat Non-serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Non-serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Dog Non-serious - 1
Digestive Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Non-serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Digestive Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Behavior Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Behavior Cat Non-serious - 1
Digestive Dog Non-serious - 1
Behavior Dog Serious - 1
Other Dog Non-serious - 1
Other Cat Non-serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Source metadata:

Documents

Owner handouts and official technical documents open on-page first, with the original source still one click away.

Owner handouts

0
No owner handouts linked yet.

Official label / PI

0
No official label or package insert links yet.

SPL

5

FOI

1

Reconcile®

SPL · SPL

Open original
FDA Structured Product Label

Reconcile®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Pegasus Laboratories, Inc.
NADA
141-272
Status
RX
Form
Tablet (Chewable)
Route
Oral
Species
Dog, No Use Class Stated Or Implied
Composition / specifications
Each chewable tablet contains 8, 16, 32, or 64 milligrams (mg) fluoxetine hydrochloride.

Dogs

Indication
For the treatment of canine separation anxiety in conjunction with a behavior modification plan.
Dosage
1 to 2 mg/kg body weight (0.5-0.9 mg/lb) once daily.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

RECONCILE SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for RECONCILE. Use the source link for the full official labeling record.

RECONCILE SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for RECONCILE. Use the source link for the full official labeling record.

RECONCILE SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for RECONCILE. Use the source link for the full official labeling record.

RECONCILE SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for RECONCILE. Use the source link for the full official labeling record.

ucm062326.pdf

FOI · FOI

Open original
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Storefront facts: Source Roxee | Refreshed May 5, 2026, 10:00 AM UTC
    The storefront fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: RECONCILE
Manufacturer mapping: Pegasus Laboratories, Inc.
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: Dog
Rx/OTC: RX
Form/route: Tablet (Chewable) • Oral
Applications: NADA 141-272
NDC: Packages 49427-340-44 49427-340-57 49427-341-44 49427-341-57 49427-342-44 49427-342-57 • Products 49427
Documents: 1 (FOI: 1) • SPL: 1 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 69 • Cat 39 • View
Case summaries: 13 (showing 8) • View
openFDA reports are unverified and do not prove causation.
Explore
Related conditions: Separation anxiety
Linked using: Fda_Label (0.95)
Diagnosis Codes

Diagnosis-code mappings are not available for this medication yet.

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Contraindication, High)
Top reaction signals
Elevated gamma-glutamyl transferase (1) Elevated alanine aminotransferase (1) Dehydration (1) Decreased mean corpuscular volume (1) Decreased mean corpuscular haemoglobin concentration (1) Decreased haemoglobin (1) Decreased appetite (1) Death by euthanasia (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
NADA: 141272 NDC Package: 49427-340-44 NDC Package: 49427-340-57 NDC Package: 49427-341-44 NDC Package: 49427-341-57 NDC Package: 49427-342-44 NDC Package: 49427-342-57 NDC Package: 49427-343-44 NDC Package: 49427-343-57 NDC Product: 49427
Package NDC Product NDC Form / Route Status
49427-340-44 49427 -
49427-340-57 49427 -
49427-341-44 49427 -
49427-341-57 49427 -
49427-342-44 49427 -
49427-342-57 49427 -
49427-343-44 49427 -
49427-343-57 49427 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

  • RECONCILE SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • RECONCILE SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • RECONCILE SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • RECONCILE SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • ucm062326.pdf • FOI summary • Official • Jan. 30, 2017
    FDA FOI summary for application 141272

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 40 Clinical 1 Manufacturer 0 Marketing 0
Current Field Facts
  • side_effects: Top reported reactions (openFDA): Vomiting, Lack of efficacy - NOS, Diarrhoea, Seizure NOS, Lethargy (see also Central nervous system depression in Neurologica… (Clinical, 2026-04-11)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Official, 2026-04-12)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Official, 2026-04-11)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Official, 2026-02-12)
  • indications: RECONCILE chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. (Official, 2026-05-05)
  • indications: RECONCILE chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. (Official, 2026-05-03)
  • indications: RECONCILE chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. (Official, 2026-05-02)
  • indications: RECONCILE chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. (Official, 2026-04-29)
  • indications: RECONCILE chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. (Official, 2026-04-28)
  • indications: RECONCILE chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. (Official, 2026-04-27)
  • indications: RECONCILE chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. (Official, 2026-04-26)
  • indications: RECONCILE chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. (Official, 2026-04-25)
  • indications: RECONCILE chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. (Official, 2026-04-22)
  • manufacturer_name: Pegasus Laboratories, Inc. (Official, 2026-05-05)
  • manufacturer_name: Pegasus Laboratories, Inc. (Official, 2026-05-03)
  • manufacturer_name: Pegasus Laboratories, Inc. (Official, 2026-05-02)
  • manufacturer_name: Pegasus Laboratories, Inc. (Official, 2026-04-29)
  • manufacturer_name: Pegasus Laboratories, Inc. (Official, 2026-04-28)
  • manufacturer_name: Pegasus Laboratories, Inc. (Official, 2026-04-27)
  • manufacturer_name: Pegasus Laboratories, Inc. (Official, 2026-04-26)
Recent Revisions
  • side_effects updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Reconcile®
RX
Fluoxetine hydrochloride
Tablet (Chewable) • Oral
Label highlights
Official documents
Pegasus Laboratories, Inc. NADA 141-272 Approved Jan 30, 2017

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
Each chewable tablet contains 8, 16, 32, or 64 milligrams (mg) fluoxetine hydrochloride.
Dogs
Indication
For the treatment of canine separation anxiety in conjunction with a behavior modification plan.
Dosage
1 to 2 mg/kg body weight (0.5-0.9 mg/lb) once daily.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Usage

For the treatment of canine separation anxiety in conjunction with a behavior modification plan.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Diarrhea (1) • Dog Decreased appetite (1) • Dog Appetite loss (1) • Dog

Showing top 5 for Digestive.

Neurologic
Unsteady walking (1) • Cat

Showing top 5 for Neurologic.

Behavior
Circling - behavioural disorder (1) • Cat Behavioral disorder (1) • Cat Anxiety (1) • Dog

Showing top 5 for Behavior.

Other
Elevated mean corpuscular volume (1) • Dog Elevated gamma-glutamyl transferase (1) • Dog Elevated creatine-kinase (1) • Dog Elevated aspartate aminotransferase (1) • Dog Elevated alanine aminotransferase (1) • Cat
Show more (20)
Electrolyte disorder (1) • Dog Disorder of red blood cell NOS (1) • Dog Dehydration (1) • Dog Decreased urine concentration (1) • Dog Decreased packed cell volume (1) • Dog Decreased mean corpuscular volume (1) • Cat Decreased mean corpuscular haemoglobin concentration (1) • Cat Decreased haemoglobin (1) • Cat Decreased haematocrit (1) • Dog Death by euthanasia (1) • Dog Death (1) • Cat Cold feeling to the touch (1) • Cat Clenched jaw (1) • Dog Chewing disorder (1) • Dog Calculi (1) • Cat Bumping into walls (1) • Dog Anaemia NOS (1) • Dog Administration error NOS (1) • Cat Abnormal tail posture (1) • Dog Abnormal radiograph finding (1) • Cat

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, ['Shepherd Dog - Australian', 'Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog)'], Male, 5 year, 14.969 kilogram • Drug: MSK, Frequency: 1 per day • Reactions: Anxiety, Clenched jaw, Shaking, Loss of voluntary movement, Stiffness limb… • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-074927
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Male
  • Age: 5.00 Year
  • Weight: 14.969 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Frequency: 1 per day
Reactions Reported:
Anxiety Clenched jaw Shaking Loss of voluntary movement Stiffness limb Falling Bumping into walls Vomiting Dehydration Hyperglycaemia Other abnormal test result NOS Tiredness (lethargy) Abnormal tail posture Stranguria Haematuria
Outcomes: Outcome Unknown

Cat, Domestic Shorthair, Female, 10 year, 3.18 kilogram • Drug: MSK, Unassigned, Oral • Reactions: Lack of efficacy (bacteria) - NOS, Upper respiratory sounds, Ocular discharge, Periorbital oedema, Vasculitis… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-074596
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 10.00 Year
  • Weight: 3.180 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Unassigned
Reactions Reported:
Lack of efficacy (bacteria) - NOS Upper respiratory sounds Ocular discharge Periorbital oedema Vasculitis Skin discolouration NOS Flaking skin Skin disorders NOS
Outcomes: Ongoing

Dog, Chihuahua, Male, 6 year, 7.7 kilogram • Drug: MSK, Unknown • Reactions: Decreased urine concentration, Proteinuria, Inappropriate urination, Weight loss • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-073869
  • Serious AE: No
  • Treated For AE: No
  • Sex: Male
  • Age: 6.00 Year
  • Weight: 7.700 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Decreased urine concentration Proteinuria Inappropriate urination Weight loss
Outcomes: Ongoing

Dog, Weimaraner, Female, 12 year, 34.019 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Recumbency, Limb weakness, Reduced reflexes, Proprioception deficit, Hind limb paresis • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-072759
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 12.00 Year
  • Weight: 34.019 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Recumbency Limb weakness Reduced reflexes Proprioception deficit Hind limb paresis
Outcomes: Ongoing

Cat, Domestic Shorthair, Female, 9 year, 3.175 kilogram • Drug: MSK, Tablet, chewable, Oral, Dose: 0.50 tablet per dose, Frequency: 1 per day • Reactions: Administration error NOS, Lack of efficacy - NOS, Intentional misuse • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-075469
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 9.00 Year
  • Weight: 3.175 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet, chewable
  • Dose: 0.50 tablet per dose
  • Frequency: 1 per day
Reactions Reported:
Administration error NOS Lack of efficacy - NOS Intentional misuse
Outcomes: Outcome Unknown

Dog, Mountain Dog - Bernese, Female, 3 year, 28.576 kilogram • Drug: MSK, Unassigned, Oral, Dose: 50 Milligram per animal • Reactions: Seizure NOS • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-072784
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Female
  • Age: 3.00 Year
  • Weight: 28.576 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Unassigned
  • Dose: 50 Milligram per animal
Reactions Reported:
Seizure NOS
Outcomes: Recovered/Normal

Dog, ['Terrier (unspecified)', 'Dog (unknown)'], Female, 7 year, 5.262 kilogram • Drug: MSK, Unassigned, Oral • Reactions: Vomiting • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-072866
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 7.00 Year
  • Weight: 5.262 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Unassigned
Reactions Reported:
Vomiting
Outcomes: Recovered/Normal

Dog, Terrier - Bull, Female, 7 year, 17.6 kilogram • Drug: MSK, Oral, Dose: 32 Milligram per animal, Frequency: 1 per day • Reactions: Leucopenia NOS, Anaemia NOS, Hypoalbuminaemia, Neutropenia, Pyoderma… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-072729
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Female
  • Age: 7.00 Year
  • Weight: 17.600 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Dose: 32 Milligram per animal
  • Frequency: 1 per day
Reactions Reported:
Leucopenia NOS Anaemia NOS Hypoalbuminaemia Neutropenia Pyoderma Reduced globulins Hypophosphataemia Non-regenerative anaemia Low serum alkaline phosphatase Pale mucous membrane Elevated alanine aminotransferase Decreased packed cell volume Tiredness (lethargy) Hypocalcaemia Elevated aspartate aminotransferase Hypoproteinaemia Proteinuria Electrolyte disorder Disorder of red blood cell NOS Elevated creatine-kinase Other coagulation investigation abnormality Increased band neutrophilia Elevated mean corpuscular volume Lymphopenia Other abnormal test result NOS Diarrhea Panleucopenia Eosinopenia Decreased haematocrit Increased percentage reticulocytes
Outcomes: Ongoing

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.